Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,582 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer.
Sakamoto J, Morita S, Yumiba T, Narahara H, Kinoshita K, Nakane Y, Imamoto H, Shiozaki H; Ascitic Gastric Cancer Study Group of the Japan South West Oncology Group. Sakamoto J, et al. Among authors: morita s. Jpn J Clin Oncol. 2003 May;33(5):238-40. doi: 10.1093/jjco/hyg048. Jpn J Clin Oncol. 2003. PMID: 12865468 Clinical Trial.
A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial.
Tsuburaya A, Sakamoto J, Morita S, Kodera Y, Kobayashi M, Miyashita Y, Macdonald JS. Tsuburaya A, et al. Among authors: morita s. Jpn J Clin Oncol. 2005 Nov;35(11):672-5. doi: 10.1093/jjco/hyi179. Epub 2005 Nov 7. Jpn J Clin Oncol. 2005. PMID: 16275676 Clinical Trial.
A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Morita S, Nakata B, Tsuji A, Mitachi Y, Shirasaka T, Saji S, Ohashi Y, Sakamoto J, Hirakawa K. Morita S, et al. Jpn J Clin Oncol. 2007 Dec;37(12):924-9. doi: 10.1093/jjco/hym124. Jpn J Clin Oncol. 2007. PMID: 18211983 Clinical Trial.
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K; North East Japan Gefitinib Study Group. Inoue A, et al. Among authors: morita s. J Clin Oncol. 2009 Mar 20;27(9):1394-400. doi: 10.1200/JCO.2008.18.7658. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224850 Clinical Trial.
3,582 results